Lung Transplantation for Pulmonary Alveolar Proteinosis - a Retrospective International Multi-Center Analysis.
Largest global analysis of lung transplants for rare lung disease fills evidence gap that guides transplant teams worldwide.
Pulmonary alveolar proteinosis is a rare lung disease where standard whole-lung lavage or GM-CSF therapy fails in a subset of patients, leaving lung transplantation as the only option. This multinational study at 37 centres across Europe, Americas, and Asia provides the largest-ever systematic outcome analysis for lung transplantation in PAP, filling a critical evidence gap that affects transplant listing decisions globally.
What the study was
- Study design
- retrospective_multicenter_cohort
- Category
- rare_diseases
- Maturity
- Validated
- Journal
- Eur Respir J
Why it surfaced
European Respiratory Journal; PAP is ultra-rare with limited transplant data; multinational 37-centre retrospective provides the best available evidence for a definitive therapy in refractory disease; design_quality capped at 1 (retrospective); abstract not retrieved—scored conservatively with medium confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.